OX40 is a member of the TNFRSF (TNF receptor superfamily). It’s predominantly expressed and is a key co-stimulatory receptor on activated T-cells. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
Hexavalent engagement of OX40 is designed to:
We believe that INBRX-106 can outperform bivalent agonists and has the potential to be widely used in combination with approved checkpoint inhibitors and also effective in tumors non-responsive to approved checkpoint inhibitors.
The Phase 1 trial for INBRX-106 is currently in Part 1, single agent dose escalation, in the following tumor types:
